ArticleAtherosclerosis plus2026
Association between serum lipoprotein(a) levels and aortic vulnerable plaques assessed by non-obstructive general angioscopy.
Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Elevated lipoprotein(a) [Lp(a)] levels are recognized as a genetic risk factor for atherosclerotic cardiovascular disease. Previous coronary imaging studies have linked elevated Lp(a) levels to vulnerable coronary plaque characteristics. However, the relationship between elevated Lp(a) levels and vulnerable aortic plaque characteristics remains unclear. We investigated the association between serum Lp(a) levels and vulnerable aortic plaque characteristics assessed by non-obstructive general angioscopy (NOGA). Methods: We analyzed 276 consecutive patients with coronary artery disease who underwent NOGA between December 2014 and March 2023. Patients were divided according to serum Lp(a) levels using a 30 mg/dL cutoff. Vulnerable aortic plaque characteristics, including plaque rupture, thrombus, yellow plaque, ulceration, and fissure, were assessed by NOGA. Results: Elevated Lp(a) levels (>30 mg/dL) were observed in 27% of patients, whereas markedly elevated Lp(a) levels (>50 mg/dL) were observed in 14%. Patients with elevated Lp(a) levels showed a significantly higher prevalence of plaque rupture (84% vs. 62%, p < 0.001), thrombus, and fissure than those with lower Lp(a) levels. In contrast, the prevalence of yellow plaque did not differ significantly between groups. The prevalence of plaque rupture progressively increased according to Lp(a) strata. In multivariate logistic regression analysis, elevated Lp(a) levels remained independently associated with plaque rupture after adjustment for traditional cardiovascular risk factors. Conclusions: Elevated serum Lp(a) levels were independently associated with aortic plaque rupture assessed by NOGA. These findings suggest that elevated Lp(a) levels may be associated with persistent aortic plaque vulnerability despite intensive LDL-C lowering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.